Pharmacovigilance exists to protect patients. Case intake exists to make that possible. Yet in most organizations, the intake process routes the majority of its time and resources through work that has nothing to do with safety assessment – transcribing calls, extracting data from PDFs, populating case fields line by line, and chasing missing information. The people best positioned to evaluate drug safety are spending their day doing data entry. That is not a staffing problem. It is a process design problem.
The core reason behind this challenge is that manual case intake is treated as a fixed operational reality by most PV teams, not as a cost with a measurable price tag. This persistent but hidden cost shows up in processing timelines, data quality failures, submission delays, follow-up gaps, and the disproportionate share of skilled reviewer time that goes toward data entry rather than medical judgment.
GenAI is changing the economics of that upstream work, not by replacing human reviewers, but by changing what they spend their time on.
The Structural Case Against Manual Intake
A study published in Clinical Pharmacology and Therapeutics found that case processing activities consume up to two-thirds of internal pharmacovigilance resources based on PVNet benchmark data. When outsourcing costs are added, case processing spending accounts – on average – for the majority of a pharmaceutical company’s total PV budget.
Case intake making up for such a significant chunk of the PV budget zooms in on the deeper problem, i.e., how the manual intake workflow is structured:
- A report arriving by phone, email, PDF, web portal, or partner form
- A trained specialist manually extracting safety information from an unstructured source
- Manual entry of patient demographics, product details, adverse event terms, and seriousness criteria into a safety database
- A quality check to catch transcription errors and incomplete fields
- A follow-up process to retrieve missing information
Each step is handled by a different person, often in a different system. IQVIA’s assessment found that a typical safety case processing workflow involves approximately five days of processing time due to the number of handovers between specialized personnel.
Five days spent moving a case through manual intake is five days before any medical evaluation begins. For expedited cases (serious and unexpected adverse reactions requiring 15-day reporting to the FDA and EMA), that timeline leaves almost no margin.
The volume of adverse event reports compounds this pressure. As of December 2023, the FAERS database contained more than 28 million reports, representing over 20 million unique cases after accounting for follow-ups and duplicates.While product portfolios are expanding and reporting channels are multiplying, the headcount required to sustain the scale of manual intake at that pace is not increasing proportionally.
The Four Failure Points of Manual Intake
The failure points in manual case intake are not random. They cluster at the same places in the workflow because the underlying causes are structural, not individual.
At data entry
Unstructured sources – call transcripts, free-text emails, PDF reports from affiliates – do not arrive in a format that maps cleanly to safety database fields. A specialist must interpret the source, determine what is relevant, and transcribe it accurately.
At high volume and under time pressure, that interpretation introduces variability. Two reviewers reading the same source document will not always extract the same data. Inconsistency in how adverse events are coded has direct downstream consequences for signal detection and aggregate reporting.
At quality reviews
Quality checks exist to catch what was overlooked during data entry. But when quality review is a manual step applied after manual entry, it is catching errors already baked into the record.
This only adds to the review time without removing the root cause.
At follow-up
Missing information does not resolve itself. Someone has to identify the incomplete fields, locate the reporter, make contact, retrieve the data, and re-enter it.
Cases that proceed without the missing information create problems at the medical review and signal assessment stages – problems that are far more costly to fix than if they had been caught at intake.
At channel fragmentation
Phone calls, emails, web portals, affiliate forms, and literature-sourced cases each arrive in different formats through different systems.
Without a unified intake architecture, each stream requires separate processes and separate oversight, multiplying the points at which errors or delays can occur.
GenAI in Case Intake: What It Changes and Why It Matters
Generative AI does not automate the medical judgment in case intake. It automates the data handling processes that precede that judgment – the extraction, structuring, and population of case fields that currently consume the majority of the team’s time.
In early pilots applying GenAI to adverse event case intake, data extraction accuracy exceeded 90%, and overall efficiency gains topped 65%. IQVIA has assessed that GenAI can be applied to approximately half of all case processing steps, including source document extraction, validation of missing data, active follow-up queries, and narrative generation.
The table below shows exactly where GenAI changes the intake workflow and what that means operationally.
Why this matters beyond efficiency
The operational gains are real, but the more consequential outcome is what happens to case quality. When data is extracted, structured, and validated at the point of intake rather than corrected after the fact, cases arrive at medical review more complete, more consistently coded, and with fewer gaps that require follow-up. That has a direct bearing on signal detection. Inconsistently coded adverse events introduce noise into aggregate safety data. Cases with missing fields delay or distort causality assessments.
In many cases, the problems that look like intake inefficiencies are the same problems that compromise the integrity of downstream safety analysis.
GenAI does not just make intake faster. It changes what the data looks like when it reaches the people who need to act on it.
The ROI of Automating Adverse Event Intake
The business case for GenAI in case intake is most clearly expressed through processing time and cost per case. However, the cost reduction is not only in direct processing time. It is also reflected in the downstream savings that follow from better data quality at intake:
Fewer quality review cycles
When automated real-time checks flag incomplete or inconsistent data during intake rather than after, quality review becomes a validation step rather than an error-correction step.
Fewer follow-up failures
Automated follow-up systems with contact optimization improve completion rates substantially. Cases that proceed without missing information do not need to be revisited later in the medical review or submission stage.
Reduced training burden
New intake staff operating with AI-guided systems reach productive capacity faster than those learning manual workflows from scratch. That reduction in onboarding time has direct cost implications in organizations with moderate staff turnover.
Increased capacity without proportional hiring
AI-assisted documentation expands intake capacity without requiring a corresponding increase in headcount. During peak periods — product launches, seasonal spikes, post-market safety reviews — teams can absorb higher case volumes without emergency staffing.
The ROI of automating pharmacovigilance intake, then, is not just a cost-per-case figure. It is the total operational cost of running an intake function that can scale with the reporting environment, maintain data quality under volume pressure, and deliver cases to medical review faster and more completely.
What GenAI Does Not Replace
GenAI can significantly improve the speed, consistency, and scalability of case intake, but it does not replace the human judgment and regulatory oversight that PV requires.
GenAI’s role is to extract information, structure it, and surface likely interpretations. It is not responsible for deciding whether a case qualifies as a valid ICSR, whether seriousness criteria have been met, or whether a causality assessment is appropriate. Those decisions remain the responsibility of qualified medical and safety professionals, and no automated system should be allowed to create final case records without their review.
The right operating model is not automation without oversight, but human-in-the-loop execution. While AI takes on the high-volume, repetitive data work, trained reviewers can focus on areas that require clinical reasoning and regulatory judgment.
This is where confidence scoring becomes especially important. High-confidence extractions can move through validation more quickly, while low-confidence outputs can be flagged for deeper human review. This keeps reviewers focused on the cases and fields that warrant their expertise, rather than applying equal attention to every entry regardless of risk.
From a compliance standpoint, under 21 CFR Part 11, Annex 11, and broader GxP expectations, any automated action within a validated pharmacovigilance environment must be fully auditable.
In practice, that means AI-assisted case intake must meet the same control standards as any other system that touches safety data. Every action must be traceable, every populated field must be attributable, and validation must be documented before the system is used in production.
The value of GenAI in case intake is real, but only when it is deployed within a framework that preserves accountability, transparency, and reviewer control.
Clinevo Case Intake Platform: What It Addresses
Clinevo’s Case Intake Platform is built specifically for pharmacovigilance intake operations, integrating AI-powered voice analytics, NLP-based document processing, and intelligent case management into a single system that covers the full intake workflow.
Multi-channel intake, unified. The platform consolidates case intake from telephone calls via AWS Connect integration, PDF and email sources, web portals, and structured affiliate forms into a single system. Each channel feeds the same intake workflow, with the same quality controls and audit trail requirements applied consistently.
Voice analytics and speech-to-text. For telephone-based case intake, real-time speech-to-text with AI comprehension enables hands-free case documentation during the call itself. This addresses one of the highest-friction points in manual intake: the specialist who must simultaneously conduct a medical conversation and manually transcribe it.
NLP for document extraction. For PDF and free-text sources, NLP identifies and extracts key safety information – adverse event details, patient demographics, product exposure, seriousness indicators – without manual document review. According to Clinevo, this reduces manual review time by 70%.
Intelligent pre-population with confidence scoring. Extracted information is automatically mapped to case fields with a confidence score attached to each populated entry. Reviewers validate high-confidence entries and focus their attention on lower-confidence or flagged fields. This reduces data entry volume by 85%.
Automated quality assurance during intake. Real-time automated checks run during the intake process, not after. Incomplete or inconsistent fields are flagged before the case record is created, reducing the rate of quality findings that require rework later in the workflow.
Intelligent case prioritization. Cases are automatically prioritized by seriousness, urgency, and medical importance. Serious adverse events are surfaced for processing first, reducing time-to-reporting from days to hours for the cases that carry the highest regulatory consequence.
Automated follow-up management. Follow-up scheduling and contact optimization are handled automatically. According to Clinevo, this improves follow-up completion rates by 90%, reducing the incidence of cases that proceed to medical review with missing information.
Compliance by design. The platform is built to HIPAA, GDPR, 21 CFR Part 11, Annex 11, and GxP standards, with encrypted transmission, secure storage, and complete audit trails. Compliance documentation is generated as part of normal operations, not assembled before an inspection.
Global reach without multilingual staffing. Multi-language identification with automatic language detection allows the platform to handle cases from diverse reporter populations without requiring dedicated multilingual intake staff for each language.
Frequently Asked Questions
GenAI replaces the transcription and extraction work that generates most entry errors. NLP extracts safety information directly from unstructured sources, and confidence scoring flags low-certainty field populations for human review rather than passing them through unchecked. Real-time quality checks during intake catch inconsistencies before the case record is created.
The most direct outcome is processing time. IQVIA has assessed that GenAI with human verification could reduce a typical five-day case processing workflow to less than a day, with potential cost reductions of up to 50% in case management costs. Beyond direct processing, the ROI also includes fewer rework cycles from quality failures, better follow-up completion, reducing downstream gaps, lower onboarding costs for new staff, and the ability to scale intake capacity during peak periods.
Manual case intake is costly because it routes the same high-volume, repetitive data handling work through trained specialists who are overqualified for data entry but required for medical review. Case processing consumes up to two-thirds of internal PV resources by some estimates, with the majority of that time spent on data handling rather than safety assessment. GenAI addresses this at the field level by extracting, structuring, and populating case data automatically, shifting specialist time toward validation and judgment rather than transcription.
LLMs trained for PV terminology can process free-text sources, including call transcripts, PDF reports, emails, and clinical notes. They identify adverse event terms, patient demographics, product exposure details, and seriousness indicators from varied narrative formats that would otherwise require manual interpretation. The output is structured data mapped to case fields, with confidence scores indicating the certainty of each extracted value. Low-confidence extractions are flagged for human review. The result is structured, reviewable case data from sources that previously required full manual processing.
